Rapamycin (Sirolimus) 化学構造
分子量: 914.18

品質と確認

製品表彰状(51)

カスタマーレビュー(9)

Quality Control & MSDS

製品情報

  • Compare mTOR Inhibitors
    mTOR阻害剤を比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

情報 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
目標

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
HT-29 NFLncm1EgXSxdH;4bYMhSXO|YYm= NIP0PFUyOCCwTR?= MmTZO|IhcA>? MWLEUXNQ NX\zZ4Y6WG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6
HT-29 NIrmNm5EgXSxdH;4bYMhSXO|YYm= MVixNEBvVQ>? M3fEWVczKGh? M1K1emROW09? M3y1fXBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=
HT-29 M{K5bGN6fG:2b4jpZ{BCe3OjeR?= M2TmR|ExKG6P M2TEXlczKGh? NF:xd4FFVVOR Mn\xVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk>
PC3 MmjnT4lv[XOnIFHzd4F6 MUWxNFAhdk1? M{GzSlEhcA>? MY\EUXNQ MVPQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?=
PC3 NED5WWVMcW6jc3WgRZN{[Xl? NUX2UW01OTByIH7N MnvLNUBp MYPEUXNQ MoDDSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?
PC3 NYrXWJFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjhNU42KM7:TR?= NGDQWYIyKGh? M4\xZmROW09? NUS5ZmFsUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N
HEK293 NWe2W4lkTnWwY4Tpc44hSXO|YYm= NEHid3YyODBibl2= MlHuPEBp NHfxZnVFVVOR M{Tj[mlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?=
BT-20 MnXCT4lv[XOnIFHzd4F6 NXu0SVRJOjBizszN MXrEUXNQ MXfEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>?
U937 M4PPS2FvfGmkYXP0[ZJq[WxiQYPzZZk> MWS1NEDPxE1? Ml\KOFghcA>? NWntN2hPTE2VTx?= NXLSTnJSUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz
U937 MnTFRY51cWKjY4TldolidCCDc4PhfS=> NGDKNms2OCEQvF2= M3SwWlQ5KGh? NF\QUHFFVVOR M33OWGRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN?
U937 MUXBcpRq[mGldHXybYFtKEG|c3H5 Mmj6OVAh|ryP NWrhN5pRPDhiaB?= MkXWSG1UVw>? NHLqXWdFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>?
MCF-7 M3K4bmF2fG:yaHHnfUBCe3OjeR?= M3riNlMxKG6P NHS2fWU1KGh? Mn7wSG1UVw>? NUXGPHE3UW6mdXPld{BifXSxcHjh[5k>
U87MG M2j5UWtqdmG|ZTDBd5NigQ>? M2DTWVEh|ryP NUP1[W1MPiCq M3LyRWROW09? MWPQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>?
U87MG M2nkfGtqdmG|ZTDBd5NigQ>? NI\TbowyKM7:TR?= M3m5OlYhcA>? MnroSG1UVw>? NWPJNm5tWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44>
U87MG NFS1WYpMcW6jc3WgRZN{[Xl? MnXUNUDPxE1? M3fUTFYhcA>? M33NVWROW09? MYfEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?
U87MG MWTLbY5ie2ViQYPzZZk> NHHtdG4yKM7:TR?= NX3Q[Y55PiCq NYKxbFY4TE2VTx?= MnPZSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v
COS7 cells expressing EGFP-HDQ74/rheb M3;mV2F2fG:yaHHnfUBCe3OjeR?= NE\NVZgxNjJizszN MlnyNlQhcA>? NGL2eXZFVVOR M3XkOmlv\HWlZYOgZZV1d3CqYXf5
COS7 cells expressing EGFP-LC3 Mo\pRZV1d3CqYXf5JGF{e2G7 MYCwMlIh|ryP NYPhfJBQOjRiaB?= NIfUUJhFVVOR M3Hne2lv\HWlZYOgZZV1d3CqYXf5
H4 M3v4cGZ2dmO2aX;uJGF{e2G7 MVmwMlIh|ryP NF3aWJMzPCCq MWLEUXNQ MmPkTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=>
HeLa M4TBeWZ2dmO2aX;uJGF{e2G7 MYmxNFAhdk1? NUD5XZhzOzZiaB?= MWrEUXNQ MVrJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u
HeLa M{\QZWZ2dmO2aX;uJGF{e2G7 MXqxNFAhdk1? MUKzOkBp MkPOSG1UVw>? NXG2c4VPUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w
HeLa NYD1bY9VTnWwY4Tpc44hSXO|YYm= MVOxNFAhdk1? MYizOkBp M{nBVmROW09? MmSzTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u
SYF NYCwRoNWTnWwY4Tpc44hSXO|YYm= NFLiWY0yODBibl2= M2LUS|I1KGh? MXLEUXNQ NIDwcpBKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44>
SYF M1;WWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLINVAxKG6P MWWyOEBp NFzRWXZFVVOR NWDTUFVXUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=>
HEK293T NGDBUpNCdnSrdnnyZYwhSXO|YYm= NH[wb4gyKG6P MWm0JIQ> M{G5[WROW09? NIXZdnNKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=>
HEK293T NYrVU|VTSW62aY\pdoFtKEG|c3H5 MkDhNUBvVQ>? MX[0JIQ> NHnuPHdFVVOR M3O1SGlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N
PBMC MXjGeY5kfGmxbjDBd5NigQ>? NXXyWmxOOSCwTR?= NU\1S24xOTRiZB?= NEDWdo5FVVOR NFrDUmVT\WS3Y3XzJGNEWjViZHXud4l1gQ>?
PBMC MVHGeY5kfGmxbjDBd5NigQ>? NX31N3JqOSCwTR?= NGKxUZoyPCCm NYPvdm0yTE2VTx?= M1nZeWRw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6
HEK293 cells NWXPWpNNU2mwYYPlJGF{e2G7 M1;PSVUxKG6P MWC0OUBucW5? MW\EUXNQ NXnySlhHUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MUnGeY5kfGmxbjDBd5NigQ>? NYPzWopmOTByIH7N NG[wVJE1KGh? MljVSG1UVw>? NH;qN4pKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>?
Human mixed lymphocyte NVfSXo9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLJOYg{PSCwTR?= M3m3VmROW09? NV7WepRLUUN3ME2xMlYhdk1w
Lewis rat lymph node cells MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz0XoU2KM7:TR?= M4HDVGROW09? MVjJR|UxRTJwNjFOwG0>
cells from the thymus of normal BALB/c mice NX\0OJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxNEBvVQ>? MlvWO|IhcA>? M{XUeGROW09? NFGzTFBKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N
MRK-nu-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnicoJKSzVyPUCuPFQ2KHCP
OCUB-M M1Lmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTCNZNFUUN3ME21MlI1KHCP
SF539 M2qxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XEZWlEPTB;MUGuOkBxVQ>?
ES4 NXKwOWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7WPYNKSzVyPUKxMlUheE1?
RL95-2 NYXleZVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO1eVBKSzVyPUGwO{BxVQ>?
LC-2-ad NGTiOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSxSlN6UUN3ME20NlMheE1?
Daudi NVPVUopHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\Le2g6UUN3ME20N|QheE1?
NTERA-S-cl-D1 NWHOV25IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR2MzDwUS=>
OS-RC-2 NH7MTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzyeGg{UUN3ME22OVIheE1?
VA-ES-BJ MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHuTWM2OD15MkOgdG0>
GR-ST M{DlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTkS2NJUUN3ME24OFYheE1?
SW872 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfHTWM2OD16NE[gdG0>
NOS-1 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHQRW14UUN3ME24O|EheE1?
MC116 NHLyd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTl6NTDwUS=>
NCI-H1355 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTOWHFyUUN3ME2xMlAyKG6P
RPMI-8226 NILIVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;kTWM2OD1zLkG5JI5O
TE-15 M{XsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jrRWlEPTB;MT6zOkBvVQ>?
Ramos-2G6-4C10 NIjvdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\QSFJDUUN3ME2xMlQ3KG6P
KU812 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnGTWM2OD1{LkCxJI5O
EW-1 NXX1UIxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwMUegcm0>
KS-1 NUHQUpJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1roTGlEPTB;Mj60OUBvVQ>?
SK-LMS-1 M3\xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGroclZKSzVyPUKuOFkhdk1?
TGBC1TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zTWM2OD1{Lk[5JI5O
TE-6 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX6TWM2OD1{Lke3JI5O
ETK-1 M3fWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK3PIFiUUN3ME2yMlgzKG6P
BE-13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwOUmgcm0>
A3-KAW NXXxV3RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPRVZFwUUN3ME2yMlk6KG6P
TE-10 M2fy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNwMzDuUS=>
DOHH-2 NGiwOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLUVpRKSzVyPUOuN|Uhdk1?
ES6 NFzHfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXruPZRyUUN3ME2zMlQ{KG6P
OPM-2 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTaeY1wUUN3ME20MlE2KG6P
SH-4 NYr5TZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;YTWM2OD12LkO0JI5O
NB13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PqN2lEPTB;ND6zOkBvVQ>?
HUTU-80 M2HE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDnZYNKSzVyPUSuOFIhdk1?
CCRF-CEM M1XwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GwPWlEPTB;ND65OEBvVQ>?
TGBC24TKB MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nRXmlEPTB;NT61NUBvVQ>?
697 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET2V4FKSzVyPU[uNlghdk1?
J-RT3-T3-5 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnFTWM2OD14LkS2JI5O
KALS-1 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZwNU[gcm0>
no-10 NFn3O3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe5RmhsUUN3ME23MlI6KG6P
SK-NEP-1 M4Lhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX0WFNKSzVyPUiuO|khdk1?
L-540 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImxcXBKSzVyPUGwMlQzKG6P
JiyoyeP-2003 M3rESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzKXI1CUUN3ME2xNE46PCCwTR?=
HH NVTRNVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\RSWtIUUN3ME2xNU4{QSCwTR?=
SR NW\sVWJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFzLkS1JI5O
QIMR-WIL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfuWnhKSzVyPUGxMlg2KG6P
A4-Fuk MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF|LkGyJI5O
CESS M{Hzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jlRmlEPTB;MUOuNVMhdk1?
KE-37 NFPDVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPHOYtKSzVyPUG2MlA4KG6P
SK-UT-1 NFH6V3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHTWm5KSzVyPUG2MlgyKG6P
SIG-M5 M{XifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF5LkK1JI5O
HT MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nCdmlEPTB;MUeuOkBvVQ>?
DEL NEjZO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXYdWo6UUN3ME2xO{46QSCwTR?=
SK-PN-DW NG\peJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS0[INkUUN3ME2yNE4zOyCwTR?=
RPMI-8402 NEP5SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILoUoNKSzVyPUKxMlc4KG6P
RPMI-6666 NYq2U|ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ2LkSyJI5O
NCI-H720 M{XJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ3LkSxJI5O
EW-16 NX;oWXFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml76TWM2OD1{Nj64O{BvVQ>?
BL-70 NV:1TXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXrTWM2OD1{OD6zPEBvVQ>?
SF126 NVjGem5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LDWmlEPTB;M{CuN|ghdk1?
BC-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v3SGlEPTB;M{GuNlYhdk1?
MHH-PREB-1 NWPQSYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfjTWM2OD1|Mj60OEBvVQ>?
A101D NFLLUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rycGlEPTB;M{KuOlIhdk1?
NMC-G1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfpTWM2OD1|Mz62O{BvVQ>?
LB1047-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\ne5pKSzVyPUO0MlY6KG6P
EM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv6TWM2OD1|OD61N{BvVQ>?
COLO-684 M4TEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN7Lkigcm0>
Becker NXG0XmZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG2TWM2OD12MT6wOUBvVQ>?
BL-41 NUfNNWp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j0SWlEPTB;NEOuOlYhdk1?
MDA-MB-134-VI NGDs[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjWSZVKSzVyPUS0MlAzKG6P
L-363 NV2wNllXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XM[2lEPTB;NESuO|Mhdk1?
ECC4 Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vDb2lEPTB;NESuO|ghdk1?
A388 NHTwUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTR2LkiyJI5O
HEL NUHqbJMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR7Lke5JI5O
RKO M1qyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojuTWM2OD13MD6yPUBvVQ>?
KINGS-1 NUXKVWRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTGTWM2OD13MT61OUBvVQ>?
EB-3 NIfBWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jFVGlEPTB;NUKuOlchdk1?
ARH-77 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PBb2lEPTB;NUKuPEBvVQ>?
GCIY MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3jTWM2OD13Mz60OkBvVQ>?
NCI-H1304 NY\ld2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTV5LkKyJI5O
KARPAS-299 NY\vcHlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnySYxKSzVyPU[xMlgzKG6P
IA-LM NX;LSXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL2OnJKSzVyPU[4MlE{KG6P
GI-1 NIq3cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXGTWM2OD15MD6zPUBvVQ>?
TE-11 M4LnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[0TWM2OD15Nz6xO{BvVQ>?
LS-411N MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLPeGJ2UUN3ME23O{42PyCwTR?=
no-11 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTTZpZKSzVyPUizMlI1KG6P
MV-4-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTh|LkezJI5O
BV-173 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TueGlEPTB;OEOuPVchdk1?
CMK NVm3R3k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPvRVRKSzVyPUi0MlE3KG6P
LC4-1 NHHuS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXwTWM2OD16Nj63NkBvVQ>?
COR-L279 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTh5LkK1JI5O
NCI-H209 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTh5LkSxJI5O
Raji Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzSTWM2OD16OT63NkBvVQ>?
LB996-RCC M2DyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTl|LkSzJI5O
NCI-H526 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PRdmlEPTB;OUOuOVkhdk1?
KGN M376RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mwSGlEPTB;OU[uNlkhdk1?
MOLT-4 MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTl4Lke5JI5O
PF-382 M1fzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS4TWM2OD17Nj63PUBvVQ>?
BC-3 NGTpcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDtTWM2OD17OT6xPEBvVQ>?
KARPAS-422 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L2PWlEPTB;MUCyMlA6KG6P
SBC-1 NX;nPXV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFyNz63OUBvVQ>?
LC-1F M2HrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnvTWM2OD1zMEiuNFUhdk1?
GB-1 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFyOT6wNkBvVQ>?
SNB75 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPLTWM2OD1zMUmuOlkhdk1?
BB65-RCC M2i4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDLTJdYUUN3ME2xNVkvQTNibl2=
NCI-N87 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm0eIROUUN3ME2xNlEvQThibl2=
IST-MEL1 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF{Mj6zPEBvVQ>?
HOP-62 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7aSm9KSzVyPUGyOk45QSCwTR?=
ACN NGPBbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojkTWM2OD1zNE[uO|Uhdk1?
DMS-114 M4HLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF3MD62O{BvVQ>?
MLMA NV7CNnBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PVTWlEPTB;MUW5Mlg5KG6P
HT-144 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fWXGlEPTB;MU[1MlQ{KG6P
C2BBe1 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPYU2lKSzVyPUG2O{44PiCwTR?=
L-428 NFfDZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D6TGlEPTB;MUe3Mlchdk1?
DU-4475 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzDUotvUUN3ME2xPFcvPjhibl2=
CP67-MEL M4nmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq3TWM2OD1zOUmuN|ghdk1?
MEG-01 NIL2SIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXhTWM2OD1{MEGuPVYhdk1?
IST-SL2 NF3YcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJyOD62N{BvVQ>?
ES8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fOeWlEPTB;MkK1Mlk1KG6P
COLO-800 M3\vcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITBRohKSzVyPUKzOU4zQCCwTR?=
MFH-ino MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnETJBKUUN3ME2yN|UvQDRibl2=
OVCAR-4 NWX3PFRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jHeWlEPTB;MkO3MlI1KG6P
PSN1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPNTWM2OD1{NEKuO|Ehdk1?
EW-12 M4DaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\tTWM2OD1{NEOuNUBvVQ>?
HCC1599 NWjLN4t6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ4MT60O{BvVQ>?
SJSA-1 NF\NPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJ5MT60OkBvVQ>?
ST486 M37UOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnmb297UUN3ME2yPVYvOTRibl2=
NOMO-1 M3v2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPOXZFKSzVyPUOwNE4zOSCwTR?=
MN-60 NI\ISFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1|MEWuN|Ihdk1?
HCC1187 NGf0W4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInJRY1KSzVyPUOwO{4zPSCwTR?=
SW982 M2ryUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnjTWM2OD1|MUSuO|Uhdk1?
LB647-SCLC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D3RWlEPTB;M{K4MlcyKG6P
HC-1 NHvEOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy1dJpKSzVyPUOzOU42KG6P
EHEB MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KydmlEPTB;M{O3MlUzKG6P
TUR NXzibGVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN4Mz65OUBvVQ>?
LU-139 NHLDb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofPTWM2OD1|N{iuNFIhdk1?
NB1 NEn4fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtWZlKSzVyPUO4OE41PSCwTR?=
BB30-HNC M1ewcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN6OD6zNkBvVQ>?
HAL-01 NF3VS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRNG9KSzVyPUO4PU4zPiCwTR?=
K5 M4P0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnvSJpuUUN3ME20NVEvOzdibl2=
MZ2-MEL MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDMfZZ1UUN3ME20NVMvPjRibl2=
RXF393 M3T0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\2UmlEPTB;NEG2MlQ2KG6P
NCI-H1648 NFSxdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRzNz61N{BvVQ>?
TE-12 M3fp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PpWGlEPTB;NEO0MlI3KG6P
EoL-1- NInUU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e0dmlEPTB;NEO3Mlk5KG6P
JAR NULZbIdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTR|OD62NkBvVQ>?
DSH1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnrZYg4UUN3ME20OVgvQTFibl2=
NCI-H187 NVzxOVdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHBTWM2OD12NkKuPFEhdk1?
HCE-4 M1TBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR5Nz62OkBvVQ>?
8-MG-BA MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvvbmNKSzVyPUW4NU42OiCwTR?=
KLE MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfZS3RKSzVyPUW4OU4zKG6P
KNS-42 NEm0bJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LSXGlEPTB;NUi2MlgyKG6P
MSTO-211H M37DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTBTWM2OD14MEmuO|Qhdk1?
GDM-1 NXLxWlZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XRVWlEPTB;NkG0MlA6KG6P
TE-1 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\EPGlEPTB;NkS2MlEzKG6P
BT-474 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZ2Nz6wOkBvVQ>?
KARPAS-45 NWD1ZldbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\4XpVKSzVyPU[0O{43KG6P
MOLT-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PybGlEPTB;NkS3Mlk{KG6P
KURAMOCHI NFz1SpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnzTFVpUUN3ME22OVcvPTFibl2=
K-562 M1;s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13WSGlEPTB;Nk[5MlUyKG6P
EKVX NUnYXpNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZ5Mj63NUBvVQ>?
GAK MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZ5NT6zJI5O
NCI-SNU-5 NIft[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHMTWM2OD14OUCuNFEhdk1?
NCI-H2126 NXnzZmdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHiO|AyUUN3ME23NlYvQDdibl2=
CTV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTd2ND65JI5O
SW962 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\FTWM2OD15NEiuOFQhdk1?
MONO-MAC-6 NIL5e4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTd3Nj65N{BvVQ>?
NCI-H748 M3naOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrrcIxQUUN3ME23OVgvQTlibl2=
NCI-H524 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTd6MD63N{BvVQ>?
LS-123 NWLF[IZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DScmlEPTB;N{m1MlY6KG6P
NB7 NUnWNJlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzIVYlzUUN3ME24NVQvOTRibl2=
LS-1034 M4PpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LiVWlEPTB;OEK4Mlk5KG6P
TE-5 NHXTNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTh6Mz61OkBvVQ>?
A704 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfRTWM2OD16OUmuNVUhdk1?
TK10 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTlzNj6wN{BvVQ>?
NCI-H345 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHQS|RKSzVyPUm0N{4zOiCwTR?=
CGTH-W-1 M3;6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vJOmlEPTB;OUS4MlE{KG6P
NCI-H510A NFnQfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPWUWJvUUN3ME25PFUvOTJibl2=
NCI-H1963 M1jOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLOR|NKSzVyPUGuNFMzQTJizszN
SCC-3 NH[3ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7KTWM2OD1zLkCzOFE1KM7:TR?=
EW-11 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwMEi3OFMh|ryP
CPC-N M17Ce2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\wTWM2OD1zLkC4PEDPxE1?
NCI-H1417 NEj2Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXRTWM2OD1zLkGyNlYh|ryP
DG-75 NV7hVoRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwMU[yPFUh|ryP
HD-MY-Z MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L6NGlEPTB;MT6xOlQyPiEQvF2=
ATN-1 M13YWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TuNWlEPTB;MT6yOlIxQSEQvF2=
KM-H2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwMk[0NFgh|ryP
NCI-H2081 NGXCc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG0eXJKSzVyPUGuNlY3OzdizszN
HL-60 M4fsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL5Z2lKSzVyPUGuNlY6PTlizszN
DB MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMkeyOFIh|ryP
NCI-H1522 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL4flVKSzVyPUGuNlg5QDdizszN
AM-38 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Sy[mlEPTB;MT6zNFczKM7:TR?=
NCI-H446 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTmUVFmUUN3ME2xMlMzOTJzIN88US=>
SU-DHL-1 NF3DV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2V3ZKSzVyPUGuN|I5ODFizszN
NH-12 NXLVZY1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TaPGlEPTB;MT6zOlM4PCEQvF2=
DMS-79 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fSN2lEPTB;MT6zOlg3PiEQvF2=
NCI-H716 M2Xwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDkSW5GUUN3ME2xMlM5QTh4IN88US=>
ML-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK2TWM2OD1zLkSxOVI6KM7:TR?=
NB10 NEfPNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFThPVBKSzVyPUGuOFY3OzJizszN
ONS-76 NUHrd29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwNUO1Olkh|ryP
LOUCY NXe2clVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwNUS2OVch|ryP
SCLC-21H NF\TWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfxTWM2OD1zLkW4OVgzKM7:TR?=
TGW NXnIdXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvSTWM2OD1zLk[zPVc2KM7:TR?=
LXF-289 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmryTWM2OD1zLkezNlY5KM7:TR?=
BB49-HNC NInOVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwN{O1PFYh|ryP
NCI-H747 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT5O2hnUUN3ME2xMlc2OzR4IN88US=>
LU-165 M1jOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwOES5PFYh|ryP
OMC-1 MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjJTWM2OD1zLkm1NFY3KM7:TR?=
RCC10RGB Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\HTWM2OD1zLkm1PFE4KM7:TR?=
SW684 NUnieoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInEN3JKSzVyPUGuPVYxQTlizszN
TE-8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\oVWlEPTB;Mj6wOVU2QSEQvF2=
SK-N-DZ MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH6TWM2OD1{LkGzNlc1KM7:TR?=
EVSA-T NWDzcGxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrzV2lKSzVyPUKuNVc{OTVizszN
KASUMI-1 NWTLPZBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nFd2lEPTB;Mj6xPFgyPSEQvF2=
NKM-1 NVnuW|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HaO2lEPTB;Mj6yOVQ4OiEQvF2=
CAL-148 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfXTWM2OD1{LkOzOlE1KM7:TR?=
NCI-H64 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwM{SyN|Ih|ryP
KNS-81-FD NVf5elVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwM{[2NkDPxE1?
KM12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf4c5lHUUN3ME2yMlQxQDN7IN88US=>
SW954 NE\5NFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJwNEe3O|kh|ryP
NCI-H1395 M33YPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LvV2lEPTB;Mj61NlY1PSEQvF2=
DJM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPqNpdKSzVyPUKuOlA3OyEQvF2=
COLO-668 NIDqNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfETWM2OD1{LkiyOlk2KM7:TR?=
NCI-H1436 NYPReYFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfkcY1KSzVyPUKuPFU3OTVizszN
LB2241-RCC M4PLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHKeXNXUUN3ME2yMlg3QDN7IN88US=>
GT3TKB Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvpSY5KSzVyPUKuPFkxPTVizszN
COLO-824 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3juPGlEPTB;Mj64PVc3QCEQvF2=
ES1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHUTWM2OD1{Lki5PFc6KM7:TR?=
LB771-HNC NI\yVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO4XlV5UUN3ME2yMlkxQTR4IN88US=>
GI-ME-N M3q4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTUTWM2OD1|LkCwPVA1KM7:TR?=
NALM-6 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrNTWM2OD1|LkCwPVM{KM7:TR?=
LU-134-A MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwMEW0NlUh|ryP
DMS-153 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HqOWlEPTB;Mz6wOVgzPCEQvF2=
MZ1-PC NXn1[ZlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zPNmlEPTB;Mz6wPVA4QCEQvF2=
NCI-H1155 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TDTGlEPTB;Mz6xNVYyKM7:TR?=
CAS-1 NFqxZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LJOWlEPTB;Mz6xN|cxPyEQvF2=
D-502MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITxXoRKSzVyPUOuNVQ{QSEQvF2=
NCI-H2141 NU\mO|hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTSRnpKSzVyPUOuNVc1PTJizszN
NB6 M{W3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\FO5BVUUN3ME2zMlE5OjV7IN88US=>
NCCIT NHPJe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2yTWM2OD1|LkKxPFA6KM7:TR?=
NB69 NEDFXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XsfmlEPTB;Mz6zNVg6OSEQvF2=
JVM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqyUHRKSzVyPUOuN|Y1OzNizszN
K052 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXzWW1kUUN3ME2zMlM4QTZ6IN88US=>
HCC2157 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G1WGlEPTB;Mz61N|IzQCEQvF2=
KMOE-2 NIrlfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwNUSyOFIh|ryP
SF268 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXCS3JHUUN3ME2zMlcyPTV2IN88US=>
CHP-126 NHT4T4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwN{[0OVgh|ryP
CP66-MEL M{THcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTiXoNjUUN3ME2zMlc6ODl2IN88US=>
NCI-H69 NHnXWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLBTWM2OD12LkCxPVM3KM7:TR?=
A253 NWHObot2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDiTWM2OD12LkCyNVAyKM7:TR?=
NB14 NF3zZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjRNoQ5UUN3ME20MlExPDd7IN88US=>
NCI-H1694 NEnybVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn6UHdKSzVyPUSuNVMyOTJizszN
NCI-H2196 NWjFOJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrqT2g5UUN3ME20MlE4OTZ7IN88US=>
TE-9 NVvIbo5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq1N4FKSzVyPUSuNVc2QDJizszN
D-283MED NHXVUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f5XWlEPTB;ND6xPFg1KM7:TR?=
OCI-AML2 NUC3UHJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRwMUm0PFkh|ryP
D-263MG MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LZXGlEPTB;ND6yNlk3OSEQvF2=
MPP-89 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K3dGlEPTB;ND6yO|MxPCEQvF2=
LAMA-84 NHLLdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIXmlEPTB;ND6zNFQzOSEQvF2=
LB373-MEL-D MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRwM{[3PFkh|ryP
UACC-257 M1fYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwM{m1N|Qh|ryP
MC-CAR NVjlfmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vxPGlEPTB;ND60N|k6KM7:TR?=
COLO-320-HSR M3vWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXicnVKSzVyPUSuOFQ1OjdizszN
P30-OHK MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7xS2hiUUN3ME20MlY3PThzIN88US=>
UACC-812 NUDXTotET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfzTmtKSzVyPUSuOlkyPjFizszN
CTB-1 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PQZmlEPTB;ND63NVU2PSEQvF2=
ALL-PO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LFWGlEPTB;ND64OFA4PyEQvF2=
SK-MEL-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH75RmFKSzVyPUSuPFY6PTVizszN
TC-YIK MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHqTXhKSzVyPUSuPVc6PDJizszN
NCI-H1882 M2D0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTVwMEKwNFEh|ryP
MHH-CALL-2 NUXw[XAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwMEWwOFIh|ryP
U-87-MG NUHDeppOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\DTWM2OD13LkC5OFY3KM7:TR?=
NCI-H1092 NF7XXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHxTWM2OD13LkK2OVU2KM7:TR?=
TE-441-T NYjEcZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjRfoZFUUN3ME21MlI4QDJizszN
SK-MEL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTVwMkmwOFQh|ryP
EW-22 M2G4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fRdmlEPTB;NT6yPVQ3PiEQvF2=
MZ7-mel MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTrSopjUUN3ME21MlQxPjlzIN88US=>
LP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq2cIpKSzVyPUWuOFEzQTFizszN
NCI-SNU-16 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rNfWlEPTB;NT62OFA4PCEQvF2=
LU-65 M1j3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTVwN{[zO|Mh|ryP
CW-2 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S3cWlEPTB;NT64OVk2QSEQvF2=
WSU-NHL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwOUWxO|Qh|ryP
IST-MES1 NX:xdpFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PUOWlEPTB;NT65OVQ1OyEQvF2=
U-266 NHrkUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTVwOUiyNFIh|ryP
TALL-1 NV[2ZYtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZwMUS2PFgh|ryP
Calu-6 NVLibHl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXqTWM2OD14LkG1N|E3KM7:TR?=
MMAC-SF MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTZwMUi1OVYh|ryP
NCI-H82 M{LMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ETWM2OD14LkKwOFg6KM7:TR?=
RS4-11 NYr4ZXZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjCTWM2OD14LkK1PFk4KM7:TR?=
SNU-C2B M4XnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL3T3h{UUN3ME22MlQxQTZ7IN88US=>
BOKU NWO5O3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHhbodKSzVyPU[uOFc2QTdizszN
C8166 NEHncXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTZwNUW5NVIh|ryP
D-247MG MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i3dWlEPTB;Nz6wOFM1PyEQvF2=
EW-18 NWPzcWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTdwMEeyPVIh|ryP
KG-1 M1O4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDvTWM2OD15Lk[yO|M5KM7:TR?=
REH M3q3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTdwNkixNFkh|ryP
U-698-M MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3xOpdWUUN3ME23Mlg1OzF3IN88US=>
KP-N-RT-BM-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrPSYE1UUN3ME23Mlk{ODJ7IN88US=>
MS-1 NYfV[2FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljSTWM2OD15Lkm2NFQyKM7:TR?=
SNU-C1 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDrTWM2OD15Lkm4NVkzKM7:TR?=
SK-MM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\6VGlEPTB;OD6yOlA3PSEQvF2=
LAN-6 NWL4TYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\o[2VKSzVyPUiuN|AxODFizszN
NEC8 M2jDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX4[ZFUUUN3ME24MlMxPjlzIN88US=>
NCI-H1770 M4q5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRThwM{iwNFIh|ryP
D-336MG M1Xad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvTOIZKSzVyPUiuOFAyOTZizszN
COLO-829 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\0Z|JKSzVyPUiuOFg5PzlizszN
LS-513 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fCemlEPTB;OD61PVU6QSEQvF2=
YT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPDO3BKSzVyPUiuOlI1OjdizszN
EW-24 NUTVNI1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXRTWM2OD16Lke2OVQh|ryP
IST-SL1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfBXVRKSzVyPUiuPFY2PDNizszN
CA46 M2P6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3kTWM2OD16Lkm1NFk5KM7:TR?=
NCI-H1838 NGnabGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELFTZZKSzVyPUiuPVg3ODJizszN
NCI-H719 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[zTWM2OD17LkK1Nlc6KM7:TR?=
HCE-T M{PWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXOboxRUUN3ME25MlMxQDVzIN88US=>
A498 NX7NW|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M163[WlEPTB;OT6zOlEzPCEQvF2=
LB831-BLC NHK2c21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPSTWM2OD17Lke2OVIyKM7:TR?=
SKM-1 NVvibZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTlwOEW5OlMh|ryP
THP-1 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzsbVB3UUN3ME25Mlk3QTF6IN88US=>
SHP-77 NWGyPYlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3naPWlEPTB;MUCuOFA4KM7:TR?=
EW-3 NVnnfoJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TxSGlEPTB;MUCuOlI5QSEQvF2=
KY821 NUXjNZZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvQO2dKSzVyPUGwMlc3OyEQvF2=
NCI-SNU-1 M2LjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XSbGlEPTB;MUGuNFIyPyEQvF2=
HCC2218 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3tb5ZKSzVyPUGxMlM6QDZizszN
IM-9 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjOZYRLUUN3ME2xNU42OTB4IN88US=>
NCI-H889 M2fIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rKPWlEPTB;MUGuOVMyOyEQvF2=
HDLM-2 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF{LkSxOVkh|ryP
LB2518-MEL NHrCS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXFZo9KSzVyPUGyMlY5OTVizszN
NCI-H23 M3fRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PkO2lEPTB;MUOuNlQzPSEQvF2=
NB17 NEPMSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjsUotsUUN3ME2xN{41PTd7IN88US=>
NCI-H322M M4HvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M170cmlEPTB;MUSuOFA3QCEQvF2=
SUP-T1 NIrEfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLCTWM2OD1zND60NVMh|ryP
ES3 NV3rUJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3XcHBmUUN3ME2xOU4xPzB|IN88US=>
ES5 NFPJNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfCNFJ1UUN3ME2xOU4xPzh5IN88US=>
NCI-H1650 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fqT2lEPTB;MUWuOFk4QSEQvF2=
NCI-H226 M3\mdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzjXYJKSzVyPUG1Mlg4PjhizszN
COR-L88 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwTWM2OD1zNj6zNVQh|ryP
SCC-15 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7QTWM2OD1zNj6zPFY6KM7:TR?=
GOTO NHz5dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF4LkS3PVMh|ryP
SIMA MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn6cHV7UUN3ME2xOk41QDB{IN88US=>
NCI-H1299 NEToPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1npU2lEPTB;MUeuNVU6OSEQvF2=
NCI-H1581 NVHYWpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXK[4RsUUN3ME2xO{41OjF7IN88US=>
MHH-NB-11 NEPB[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zLdmlEPTB;MUeuPVY5OyEQvF2=
MFM-223 NVmyXYl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe3S45KSzVyPUG4MlA2OzhizszN
ES7 NXGwVJFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M162UmlEPTB;MUiuOVQ{OSEQvF2=
JVM-3 NYLFOnBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPm[3lKSzVyPUG4MlcyPyEQvF2=
RL MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjsdpRKSzVyPUKwMlM5QCEQvF2=
EC-GI-10 NVj5OZNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJzLkKwOFEh|ryP
LNCaP-Clone-FGC Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu0TWM2OD1{MT62O|Y5KM7:TR?=
IMR-5 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHSUGF3UUN3ME2yNU45PDl2IN88US=>
KP-N-YS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFiz[4hKSzVyPUKxMlg4PSEQvF2=
Mo-T NG\QfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXm[oNKSzVyPUKyMlIyQDVizszN
NCI-H128 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW3NYNKSzVyPUKzMlU5PTNizszN
RH-1 M3ziW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGxdIFKSzVyPUKzMlc5PjZizszN
NCI-H2171 M1;Kdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXVR|ZwUUN3ME2yOE4zPDh3IN88US=>
RPMI-8866 NYK5R|FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ4Lke0NkDPxE1?
SK-N-FI MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD0TWM2OD1{Nz6zPFEyKM7:TR?=
LOXIMVI MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WweWlEPTB;MkeuPFA2OSEQvF2=
P31-FUJ NFnZelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNzLkWzO|Qh|ryP
KMS-12-PE NVLhN|RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR7LkWzNFIh|ryP

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞系 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
処理時間 72 hours
方法

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
管理 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーレビュー (9)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

製品表彰状 (51)

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related mTOR 阻害剤

  • Zotarolimus(ABT-578)

    Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.

    Features:Zotarolimus has a shorter in vivo half-life and is also demonstrated in rats to have less potent systemic immunosuppression than rapamycin.

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • LY2090314

    LY2090314 は GSK-3α と GSK-3βのために、強力なGSK-3阻害剤で、IC50 がそれぞれ1.5 nM と 0.9 nMです。

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

最近見られたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ